| 1 |
35636725 | The pathogenesis of, and pharmacological treatment for, Canavan disease. | 2022 May 27 |
3 |
| 2 |
33304759 | Cell-Based Therapy for Canavan Disease Using Human iPSC-Derived NPCs and OPCs. | 2020 Dec |
2 |
| 3 |
27531131 | Two patients with Canavan disease and structural modeling of a novel mutation. | 2017 Feb |
4 |
| 4 |
28879565 | Comparative computational assessment of the pathogenicity of mutations in the Aspartoacylase enzyme. | 2017 Dec |
4 |
| 5 |
26586007 | Atypical clinical and radiological course of a patient with Canavan disease. | 2016 Apr |
1 |
| 6 |
26797702 | Structural modeling of p.V31F variant in the aspartoacylase gene. | 2016 Jun |
2 |
| 7 |
27089954 | Modeling the Complete Catalytic Cycle of Aspartoacylase. | 2016 May 12 |
2 |
| 8 |
27288788 | Non-genetic therapeutic approaches to Canavan disease. | 2016 Jul 15 |
3 |
| 9 |
25189319 | Short-term cuprizone feeding verifies N-acetylaspartate quantification as a marker of neurodegeneration. | 2015 Mar |
1 |
| 10 |
25573156 | Acetate supplementation as a means of inducing glioblastoma stem-like cell growth arrest. | 2015 Aug |
1 |
| 11 |
23996800 | Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma. | 2014 Mar 15 |
1 |
| 12 |
24977939 | Canavan disease: clinical features and recent advances in research. | 2014 Aug |
2 |
| 13 |
25003821 | Aspartoacylase catalytic deficiency as the cause of Canavan disease: a structural perspective. | 2014 Aug 5 |
1 |
| 14 |
22850825 | Relationship between enzyme properties and disease progression in Canavan disease. | 2013 Jan |
1 |
| 15 |
23151389 | Canavan disease, a rare early-onset human spongiform leukodystrophy: insights into its genesis and possible clinical interventions. | 2013 Apr |
2 |
| 16 |
23884408 | N-acetylaspartate (NAA) and N-acetylaspartylglutamate (NAAG) promote growth and inhibit differentiation of glioma stem-like cells. | 2013 Sep 6 |
2 |
| 17 |
24278309 | Acetate supplementation induces growth arrest of NG2/PDGFRα-positive oligodendroglioma-derived tumor-initiating cells. | 2013 |
1 |
| 18 |
22468686 | A novel aspartoacylase (ASPA) gene mutation in Canavan disease. | 2012 Aug |
2 |
| 19 |
22611636 | A mutation of aspartoacylase gene in a Turkish patient with Canavan disease. | 2012 |
2 |
| 20 |
23253610 | Long-term follow-up after gene therapy for canavan disease. | 2012 Dec 19 |
3 |
| 21 |
21474353 | A safety trial of high dose glyceryl triacetate for Canavan disease. | 2011 Jul |
4 |
| 22 |
20673702 | Upregulation of N-acetylaspartic acid resulting nitric oxide toxicity induces aspartoacylase mutations and protein interaction to cause pathophysiology seen in Canavan disease. | 2010 Dec |
6 |
| 23 |
19319678 | Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease? | 2009 Sep |
1 |
| 24 |
17275978 | N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. | 2007 Feb |
3 |
| 25 |
16647192 | Canavan disease and the role of N-acetylaspartate in myelin synthesis. | 2006 Jun 27 |
3 |
| 26 |
16802706 | Canavan disease: studies on the knockout mouse. | 2006 |
3 |
| 27 |
16807907 | Canavan disease: a white matter disorder. | 2006 |
1 |
| 28 |
17177147 | Natural history of Canavan disease revealed by proton magnetic resonance spectroscopy (1H-MRS) and diffusion-weighted MRI. | 2006 Aug |
4 |
| 29 |
15784740 | Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease. | 2005 Apr 5 |
2 |
| 30 |
16217711 | Atypical MRI findings in Canavan disease: a patient with a mild course. | 2005 Oct |
1 |
| 31 |
10837925 | Murine aspartoacylase: cloning, expression and comparison with the human enzyme. | 2000 May 5 |
1 |
| 32 |
20301412 | Canavan Disease | 1993 |
1 |